Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
633.00    -1.00 (-0.16%)
Bid:
627.00
Ask:
629.00
Spread: 2.00 (0.319%)
Market Cap: £766.16m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

OXB to present at JMP Securities

23 Jun 2015 12:00

RNS Number : 9633Q
Oxford Biomedica PLC
23 June 2015
 

 

Oxford BioMedica to present at JMP Securities Life Sciences Conference 2015 in New York and to attend ROTH Healthcare Day in London

 

Oxford, UK - 23 June 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that Chief Executive Officer John Dawson will present today at the 2015 JMP Securities Life Sciences Conference in New York at 1600-1630 ET (2100-2130 BST).

 

Tim Watts, Chief Financial Officer of Oxford BioMedica will also be in attendance at the 2nd Annual ROTH Healthcare Day, held in London on the 24th June 2015.

A live-streaming webcast of the JMP conferencepresentation will be available at http://wsw.com/webcast/jmp27/oxb.l. An archived copy of the presentation will also be made available on the Oxford BioMedica website following the event.

- Ends -

 

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton

 

 

 

Tel: +44 (0)20 3709 5700

 

Notes for editors

 

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that

are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAPKNDQKBKDCAB
Date   Source Headline
19th Feb 20269:44 amRNSRule 2.9 Announcement
19th Feb 20268:04 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
19th Feb 20267:54 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
18th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
18th Feb 20262:37 pmRNSForm 8.3 - Oxford Biomedica Plc
18th Feb 20269:32 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
18th Feb 20269:18 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
17th Feb 202610:21 amRNSForm 8.5 (EPT/NON-RI) Oxford Biomedica Plc
17th Feb 202610:15 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
17th Feb 202610:11 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
16th Feb 20263:15 pmRNSForm 8.5 (EPT/RI)- Replacement of Oxford Biomedica
16th Feb 20262:53 pmRNSForm 8.3 - Oxford Biomedica Ltd
16th Feb 20262:51 pmRNSForm 8.3 - Oxford Biomedica Plc
16th Feb 20262:28 pmEQSForm 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
16th Feb 20261:35 pmRNSForm 8.3 - Oxford Biomedica plc
16th Feb 202611:08 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
16th Feb 202611:07 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
16th Feb 202611:07 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
16th Feb 20269:36 amRNSForm 8.5 (EPT/NON-RI) Oxford Biomedica Plc
13th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
13th Feb 20267:36 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
13th Feb 20267:32 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
12th Feb 20268:13 pmEQSForm 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
12th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
12th Feb 20261:20 pmRNSForm 8.3 - Oxford Biomedica plc
12th Feb 20267:46 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
12th Feb 20267:42 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
11th Feb 20263:01 pmRNSExtension of PUSU Deadline
11th Feb 202610:24 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
11th Feb 202610:19 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
10th Feb 202610:40 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
10th Feb 202610:33 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
10th Feb 202610:32 amRNSForm 8.5 (EPT/NON-RI) Oxford Biomedica Plc
9th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
9th Feb 202610:45 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
9th Feb 202610:38 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
6th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
6th Feb 20269:52 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
6th Feb 20267:00 amRNSRule 2.9 Announcement
5th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
5th Feb 20262:34 pmRNSForm 8.5 (EPT/RI) - Replacement of Oxford Biomedi
5th Feb 20262:21 pmRNSForm 8.3 Oxford Biomedica plc
5th Feb 20261:52 pmRNSForm 8.3 Oxford Biomedica plc
5th Feb 202610:46 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
5th Feb 202610:41 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
5th Feb 20267:00 amRNSRule 2.9 Announcement
4th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
4th Feb 202610:41 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
4th Feb 202610:38 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
4th Feb 20267:00 amRNSMulti-year supply agreement with BMS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.